Significant Ownership of STEMPOINT CAPITAL LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for STEMPOINT CAPITAL LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Sean C. Tan - Sean C. Tan, Authorized Signatory
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow STEMPOINT CAPITAL LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from STEMPOINT CAPITAL LP
Significant Ownership of STEMPOINT CAPITAL LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics, Inc. | Common Stock, $0.0001 par value per share | 9.9% | $4,006,121 | 132,873 | StemPoint Capital LP | 31 Mar 2026 | ||
| XLO | Xilio Therapeutics, Inc. | Common stock, par value $0.0001 per share | 8.4% | $3,979,818 | +$1,339,818 | 6,030,028 | +51% | StemPoint Capital LP | 31 Dec 2025 |
| SRZN | Surrozen, Inc. | Common Stock, $0.0001 par value per share | 4.5% | $15,695,581 | -$2,810,632 | 525,639 | -15% | StemPoint Capital LP | 31 Mar 2026 |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, par value $0.001 per share | 1.5% | $456,394 | -$1,266,690 | 616,749 | -74% | StemPoint Capital LP | 31 Dec 2025 |
Schedules 13D/G Reported by STEMPOINT CAPITAL LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.